Despite challenges, CAR-T may have ‘expanded role’ for children

121227

February 23, 2021

9 min read

Source/Disclosures

Published by:

Source: Healio Interviews

Disclosures: Brown reports scientific advisory board roles with Kite Pharma and Novartis. Gardner reports honoraria from Novartis. Maude reports consultant roles with Kite Pharma and Novartis. Rouce reports honoraria from Kite Pharma/Gilead and Novartis and research funding from Tessa Therapeutics.

ADD TOPIC TO EMAIL ALERTS

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

ADDED TO EMAIL ALERTS

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Chimeric antigen receptor T-cell therapy has been heralded as a transformative addition to the cancer treatment armamentarium.

Adoption of these therapies for treatment of younger patients, however, has been much less widespread.

“There are far fewer centers that offer CAR-T for children,” Rebecca A. Gardner, MD, associate professor in the department of pediatrics at University of Washington and attending physician at Seattle Children’s Hospital, told Cell Therapy Next…

Want to know more click here go to source.

From -
Close
Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages

Site Language


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close